Back

SGLT2 Inhibitors - Diabetes or renal drugs?

2 September 2019 (13:15 - 13:25)
Organised by:
Congress Presentation Part of: Evidence-based treatment of patients with SGLT-2is - What do we know and what is missing? Diabetes and the Heart ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Per-Henrik Groop

University of Helsinki, Helsinki (Finland)

6 More presentations in this session

Presentation thumbnail
Welcome and opening remarks
Professor D. McGuire (Dallas, US)
Slides Video
Presentation thumbnail
What is the role for SGLT2is for patients with heart failure? A cardiologist’s view
Professor G. Filippatos (Athens, GR)
Slides Video
Presentation thumbnail
Ertugliflozin and the VERTIS program – What have we learned to date?
Professor L. Leiter (Toronto, CA)
Slides Video
Presentation thumbnail
Questions and answers
Slides Video
Presentation thumbnail
Bringing forward the future of SGLT2 inhibitors in the treatment of patients with diabetes and cardiovascular disease - A roundtable dscussion
Professor P. Groop (Helsinki, FI) Professor D. McGuire (Dallas, US) Professor G. Filippatos (Athens, GR) Professor L. Leiter (Toronto, CA)

Access the full session

Session thumbnail
Evidence-based treatment of patients with SGLT-2is - What do we know and what is missing?

The Event

Event poster

ESC Congress 2019

2 September 2019 13:15 CET
You may be interested in
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level
thumbnail
Congress Session
Diabetes, obesity, and heart failure
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources